Find in Library

Malignant peritoneal effusions often arise in patients with of ovarian cancer. They are dangerous complication of cancer. Intraperitoneal chemotherapy isn’t always effective and causes side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2 / lymphokine activated killers (LAK) biotherapy is characterised of high efficacy in ovarian cancer patients with malignant peritoneal effusions. The objective effect was 82,6 % аnd 72,0 % accordingly. These results suggest that intraperitoneal biotherapy allows to expand possibilities of malignant peritoneal effusions treat- ment in ovarian cancer patients.